The FDA faced sharp scrutiny over its Commissioner’s National Priority Voucher (CNPV) pilot at a June 4 listening session, with stakeholders offering mixed reviews of the program’s accelerated review timeline and how it’s being implemented. The agency’s voucher pathway is designed to tighten sponsor-review communication and shorten timelines versus standard priority review.